Last reviewed · How we verify
NCT04343157: IG-SRS
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
Phase 2 trial testing Cognitive Sparing Brain Stereotactic Radiosurgery (SRS) in Brain Metastases, Adult in 60 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Jona Hattangadi-Gluth |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 May 2019 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)
Conditions studied
- Brain Metastases, Adult — all drugs for Brain Metastases, Adult →
- Neurocognitive Function — all drugs for Neurocognitive Function →
- Cancer — all drugs for Cancer →
Sponsor
Jona Hattangadi-Gluth
Who can join
18 and older, any sex, with Brain Metastases, Adult or Neurocognitive Function. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Preservation of neurocognitive function in the treatment of brain metastases.
Parsons MW, Peters KB, Floyd SR, Brown P, et al · · 2021 · cited 16× · PMID 34859237 · DOI 10.1093/noajnl/vdab122 -
Precision Radiotherapy for Gliomas: Implementing Novel Imaging Biomarkers to Improve Outcomes With Patient-Specific Therapy.
Connor M, Kim MM, Cao Y, Hattangadi-Gluth J. · · 2021 · cited 4× · PMID 34570449 · DOI 10.1097/ppo.0000000000000546 -
Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies - a comprehensive review.
Chen H, Li S, Yang Q, Zhou F. · · 2026 · PMID 42109678 · DOI 10.3389/fonc.2026.1821752 -
The role of diffusion-weighted MRI in biological image-guided radiation therapy: a roadmap.
Deng J, Tadimalla S, Seibert TM, Gach HM, et al · · 2026 · PMID 41956106 · DOI 10.1088/1361-6560/ae5d80 -
Neurocognitive outcomes in patients with brain metastases: a systematic review.
Bou Dargham T, Winter SF, Batich K, Gehring K, et al · · 2025 · PMID 41308688 · DOI 10.1016/s1470-2045(25)00525-x
Verify or expand the search:
- PubMed search for NCT04343157
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Metastases, Adult
Currently open trials in the same condition.
- NCT07448662 — Local Treatment Strategies for Brain Metastases of Colorectal Cancer · active not recruiting
- NCT07198256 — AI-assisted Diagnosis of Malignant Brain Tumors · recruiting
- NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
- NCT06209567 — A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors · EARLY_PHASE1 · active not recruiting
- NCT06280300 — Multi-disciplinary Care for Brain Metastases · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04343157 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jona Hattangadi-Gluth
- Last refreshed: 18 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04343157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing